Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #137 7/14/2022

7/13/2022

 
COVID-19 Vaccines

The FDA issued an EUA for the Novavax COVID-19 Vaccine, on 7/13/2022, to prevent COVID-19 in patients 18 years of age and older. The Novavax COVID-19 Vaccine is administered as a two-dose primary series given three weeks apart. 

Johns Hopkins’ researchers prospectively followed rheumatic and musculoskeletal diseases and solid organ transplant recipients patients who had been vaccinated with either the Pfizer-BioNTech or Moderna COVDI-19 vaccines. While the immune response was similar in patients not receiving immunosuppression the response was higher with the Moderna vaccine in patients receiving immunosuppressive drugs.
 
Moderna announced that an experimental COVID-19 bivalent vaccine containing a combination of the original vaccine and an Omicron BA.1 subvariant specific vaccine, elicited antibody levels for Omicron BA.4 and BA.5 subvariants that were 1.69 times higher than the original vaccine. Moderna is also developing a vaccine targeting the Omicron BA.4 and BA.5 subvariants.
 
COVID-19 Antivirals
 
The FDA rejected a request for an EUA for aviptadil to treat critical COVID-19 with respiratory failure and to treat COVID-19 patients, in November 2021.
 
In June 2022, the FDA rejected a request for an EUA for aviptadil to treat COVID-19 respiratory failure patients who continue to worsen, despite treatment with remdesivir.
 
COVID-19 Anti-Inflammatories
 
Humanigen announced that in the 29-day, 473 patient, NIAID sponsored, Phase II, ACTIV-5/BET-B trial(NCT04583969), adding lenzilumab to remdesivir did not reduce the need for mechanical ventilation compared to remdesivir monotherapy in hospitalized patients with COVID-19.
 
Sabizabulin is an oral microtubule disruptor being developed by Veru as a treatment for metastatic castration-resistant prostate cancer. Because sabizabulin has been shown to have antiviral effects on the S protein-microtubule trafficking and anti-inflammatory effects, Veru is evaluating the drug as a treatment for cytokine release syndrome (cytokine storm) induced by COVID-19.
  • Veru announced that in a 29-day, 40 patient, Phase II trial, treatment with sabizabulin resulted in an 82% reduction in mortality, 73% reduction in ICU days and 78% reduction in ventilator days compared to placebo in hospitalized COVID-19 patients at high risk for ARDS.
  • Interim results from a 150 patients enrolled in a 60-day, 204 patient, Phase III trial (NCT04842747), found that treatment with sabizabulin resulted in a 20.2% mortality rate compared to a 45.1% rate in hospitalized patients with moderate to severe COVID-19 at high risk for ARDS or death. Compared to placebo, treatment with sabizabulin resulted in a 43% reduction in ICU days, 49% reduction in ventilator days and 26% reduction in hospital days.

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.